Acta Neuropathologica

, Volume 123, Issue 5, pp 751–752

Natalizumab-associated complication? First case of peripheral T cell lymphoma

  • Jeffrey Schowinsky
  • John Corboy
  • Timothy Vollmer
  • B. K. Kleinschmidt-DeMasters
Correspondence

References

  1. 1.
    Bergamaschi R, Montomoli C (2009) Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence? Mult Scler 15:1532–1533PubMedCrossRefGoogle Scholar
  2. 2.
    Berger JR, Houff S (2009) Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann Neurol 65:367–377PubMedCrossRefGoogle Scholar
  3. 3.
    Clifford DB, DeLuca A, Simpson DM et al (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9:438–446PubMedCrossRefGoogle Scholar
  4. 4.
    Fox R (2011) Advances in the management of PML: focus on natalizumab. Cleve Clin J Med 78:S33–S37PubMedCrossRefGoogle Scholar
  5. 5.
    Ismail A, Kemp J, Sharrack B (2009) Melanoma complicating treatment with Natalizumab (Tysabri) for multiple sclerosis. J Neurol 256:1771–1772PubMedCrossRefGoogle Scholar
  6. 6.
    Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353:369–374PubMedCrossRefGoogle Scholar
  7. 7.
    Kotlyar DS, Osterman MT, Diamond RH et al (2011) A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 9:36–41PubMedCrossRefGoogle Scholar
  8. 8.
    Langer-Gould A, Atlas SW, Green AJ et al (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375–381PubMedCrossRefGoogle Scholar
  9. 9.
    Laroni A, Bedognetti M, Uccelli A et al (2011) Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. Neurol Sci 32:181–182PubMedCrossRefGoogle Scholar
  10. 10.
    Mullen JT, Vartanian TK, Atkins MB (2008) Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 358:647–648PubMedCrossRefGoogle Scholar
  11. 11.
    Panzara MA, Bozic C, Sandrock AW (2008) More on melanoma with transdifferentiation. N Engl J Med 359:99PubMedCrossRefGoogle Scholar
  12. 12.
    Polman CH, O’Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910PubMedCrossRefGoogle Scholar
  13. 13.
    Schweikert A, Kremer M, Ringel F et al (2009) Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 66:403–406PubMedCrossRefGoogle Scholar
  14. 14.
    Stuve O, Wiendl H (2009) Iatrogenic immunosuppression with biologics in MS: expecting the unexpected? Neurology 73:1346–1347PubMedCrossRefGoogle Scholar
  15. 15.
    Van Assche G, Van Ranst M, Sciot R et al (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 353:362–368PubMedCrossRefGoogle Scholar
  16. 16.
    Vavricka BM, Baumberger P, Russmann S, Kullak-Ublick GA (2010) Diagnosis of melanoma under concomitant natalizumab therapy. Mult Scler 17:255–256PubMedCrossRefGoogle Scholar
  17. 17.
    Zecca C, Nessi F, Bernasconi E, Gobbi C (2009) Ocular toxoplasmosis during natalizumab treatment. Neurology 73:1418–1419PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Jeffrey Schowinsky
    • 1
  • John Corboy
    • 2
  • Timothy Vollmer
    • 2
  • B. K. Kleinschmidt-DeMasters
    • 1
    • 2
    • 3
  1. 1.Department of Pathology, Anschutz Medical CampusUniversity of Colorado at DenverAuroraUSA
  2. 2.Department of Neurology, Anschutz Medical CampusUniversity of Colorado at DenverAuroraUSA
  3. 3.Department of Neurosurgery, Anschutz Medical CampusUniversity of Colorado at DenverAuroraUSA

Personalised recommendations